Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEX:CRL's Equity-to-Asset is ranked worse than 75.71% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs MEX:CRL: 0.38
Charles River Laboratories International (MEX:CRL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Charles River Laboratories International Equity-to-Asset Related Terms
Charles River Laboratories International Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International Equity-to-Asset Chart
Charles River Laboratories International Annual Data
MEX:CRL vs RVTY, ICLR, QGEN: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Equity-to-Asset falls into.
Charles River Laboratories International Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (MEX:CRL) has a Equity-to-Asset of 0.38 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Charles River Laboratories International and its competitors. This is near median its historical median of 0.36. Over the past decade, Charles River Laboratories International's Equity-to-Asset has ranged from 0.31 to 0.47. According to the industry distribution chart, Charles River Laboratories International ranks #159 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 75.7%.
Is Charles River Laboratories International's Equity-to-Asset too high?
Charles River Laboratories International's current Equity-to-Asset of 0.38 is near median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.31 to a high of 0.47. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Charles River Laboratories International's value of 0.38 is 35.6% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #159 out of 210 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Charles River Laboratories International has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Equity-to-Asset compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #159 out of 210 companies for Equity-to-Asset. This places Charles River Laboratories International in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Charles River Laboratories International's value of 0.38 is 35.6% below this benchmark. Historically, Charles River Laboratories International's own Equity-to-Asset has ranged from 0.31 to 0.47 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.59, Charles River Laboratories International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current Equity-to-Asset of 0.38 is 35.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current Equity-to-Asset is 0.38, which is near median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (MEX:CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,782.12, compared to a current price of MXN4,720.00 — trading 69.7% above its estimated fair value. The current Equity-to-Asset is 0.38, which is near median its 10-year median of 0.36 and 35.6% below the Medical Diagnostics & Research industry median of 0.59. Charles River Laboratories International's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Charles River Laboratories International (MEX:CRL), the current Equity-to-Asset is 0.38 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (MEX:CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of MXN4,720.00 is trading 69.7% above its estimated GF Value™ of MXN2,782.12.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for MEX:CRL:
Equity-to-Asset: 0.38 (near median its 10-year median of 0.36)
GF Value™: MXN2,782.12 vs. price of MXN4,720.00 (69.7% above fair value)
Industry Position: 35.6% below the Medical Diagnostics & Research median (#159 of 210)
No single metric tells the full story. See the MEX:CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
52GF Score
Get the complete analysis for MEX:CRL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CRL has been successfully added to your 
